Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

Eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma share some pathophysiological key features related to the vascular and tissue eosinophilic infiltration and the cytokine cascade it mediates.1,2 Given the consistent reduction in blood eosinophils and their pathogenic effects in patients with severe asthma treated with mepolizumab at the dose of 100 mg/4 wk, the same drug has been explored in patients with EGPA.1...